MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Sarepta Therapeutics Inc

Deschisă

SectorSănătate

60.96 0.18

Rezumat

Modificarea prețului

24h

Curent

Minim

59.75

Maxim

61.86

Indicatori cheie

By Trading Economics

Venit

125M

159M

Vânzări

191M

658M

P/E

Medie Sector

23.603

57.333

EPS

1.9

Marjă de profit

24.156

Angajați

1,372

EBITDA

138M

187M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+140.04% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-5.3B

5.4B

Deschiderea anterioară

60.78

Închiderea anterioară

60.96

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Sarepta Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mar. 2025, 14:19 UTC

Principalele dinamici ale pieței

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20 iun. 2024, 23:05 UTC

Principalele dinamici ale pieței

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21 iun. 2024, 08:58 UTC

Top știri

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Comparație

Modificare preț

Sarepta Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

140.04% sus

Prognoză pe 12 luni

Medie 148.25 USD  140.04%

Maxim 209 USD

Minim 70 USD

În baza a 22 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSarepta Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

22 ratings

18

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

59.31 / 62.78Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.